publicado em 31/12/2012 às 09h00:00
   Dê o seu voto:

United States approves new drug to reduce symptoms of chickenpox

Varizig is approved for children and immunocompromised adults, newborns, pregnant women and premature babies

font size

The U.S. Food and Drug Administration has approved Varizig for reducing the severity of chicken pox (varicella zoster virus) infections in high risk individuals when given within four days after exposure.

Varizig is a varicella zoster immune globulin preparation. Varicella zoster virus (VZV) causes chickenpox in children and shingles in adults. Varizig is the only FDA approved immune globulin for VZV after exposure available in the United States. It was designated as an orphan drug by the FDA and received a priority review.

Most people in the United States have immunity to VZV from vaccination or from having had chickenpox during childhood. However, people without immunity to VZV who are exposed to the virus may experience severe infections that are sometimes fatal.

People most at risk include children or adults with weakened immune systems, pregnant women, and infants exposed during pregnancy or after birth. Occasionally, healthy people without immunity to VZV may contract severe infections. Antiviral treatments are not always effective and cannot be used in some cases.

" This approval fills an unmet need by providing a treatment to lower the risk of severe, potentially fatal varicella infections in vulnerable patients," said Karen Midthun, M.D., director of the FDA' s Center for Biologics Evaluation and Research.

Varizig is an antibody preparation manufactured from plasma of healthy donors with high anti-VZV antibody levels. The donated plasma comes from FDA-licensed collection facilities in the United States and Canada. Varizig is administered in two or more injections, depending on the weight of the recipient, within 96 hours after exposure. Varizig is approved for immuno-compromised children and adults, newborns, pregnant women, premature infants, children less than a year old, and adults with no immunity to VZV.

Varicella zoster immune globulin (VZIG) has been shown to lower the risk of severe infections if given soon enough after exposure. An earlier FDA-licensed VZIG was removed from the U.S. market by the manufacturer in 2006, and Varizig has only been available under an investigational expanded access protocol during the licensing process.

In studies Varizig was shown to be comparable to VZIG and was as effective as VZIG in preventing infection during pregnancy. Data on Varizig collected from individuals treated under the expanded access protocol showed a low rate of severe VZV infection in susceptible individuals compared with the rate in untreated individuals.

The studies also showed that Varizig is safe for its intended use, with the most common side effects being pain at the injection site and headache.

   Palavras-chave:   Chickenpox    Chickenpox    Food and Drug Administration    FDA    Karen Midthun   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: United States approves new drug to reduce symptoms of chickenpox
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: United States approves new drug to reduce symptoms of chickenpox

Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
Chickenpox    chickenpox    Food and Drug Administration    FDA    Karen Midthun   
Leave your comment
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story:
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaú
Get the newsletter of the portal  iSaú
Recommend the portal iSaú
News from  iSaú in your blog or website.
Get news on the subject of your interest.
© 2000-2011 Todos os direitos reservados.